Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000726595 | SCV000345743 | uncertain significance | not provided | 2016-09-20 | criteria provided, single submitter | clinical testing | |
Genetic Services Laboratory, |
RCV000404503 | SCV000596512 | uncertain significance | not specified | 2016-08-30 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002480060 | SCV000894878 | uncertain significance | Autosomal recessive limb-girdle muscular dystrophy type 2O; Muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B3; Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A3; Retinitis pigmentosa 76 | 2021-12-16 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001213923 | SCV001385580 | uncertain significance | Autosomal recessive limb-girdle muscular dystrophy type 2O; Muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B3 | 2022-10-04 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with glycine, which is neutral and non-polar, at codon 486 of the POMGNT1 protein (p.Arg486Gly). This variant is present in population databases (rs534543454, gnomAD 0.002%). This variant has not been reported in the literature in individuals affected with POMGNT1-related conditions. ClinVar contains an entry for this variant (Variation ID: 291060). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt POMGNT1 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV002518155 | SCV003747235 | uncertain significance | Inborn genetic diseases | 2022-07-24 | criteria provided, single submitter | clinical testing | The c.1456C>G (p.R486G) alteration is located in exon 17 (coding exon 16) of the POMGNT1 gene. This alteration results from a C to G substitution at nucleotide position 1456, causing the arginine (R) at amino acid position 486 to be replaced by a glycine (G). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Revvity Omics, |
RCV000726595 | SCV003811728 | uncertain significance | not provided | 2023-09-27 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001833416 | SCV002089599 | uncertain significance | Muscle eye brain disease | 2020-08-24 | no assertion criteria provided | clinical testing |